RxDoctor Payments Data

James Simon

Gynecology · Washington, DCNPI 1700947256

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $497,732 of the $811,209 with a category attached, or 61.4%. 40 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 40.4% of the total.

$811,209in general payments, 2019–2025

Across 810 payments — averaging $1001.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$328K
  • AbbVie$104K
  • Therapeuticsmd, Inc.$81K
  • Bayer$79K
  • AMAG Pharmaceuticals, Inc.$42K
  • Astellas Pharma US Inc$38K
  • plus $138K from 34 others
$1,218,187in research payments, 2019–2025

Across 389 payments — averaging $3131.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$650K
  • Sumitomo Pharma America, Inc.$236K
  • Bayer$156K
  • Mylan Inc.$107K
  • Myovant Sciences GmbH$33K
  • Mylan Technologies Inc.$28K
  • plus $9K from 3 others

What the payments were for

  • Consulting fees$185,12823%
  • Speaking & faculty fees$497,73261%
  • Travel & lodging$101,91713%
  • Food & beverage$25,5543%
  • Education$8570%
  • Gifts$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol84$15,486
Estradiol (Twice Weekly)Estradiol123$14,180
PremarinEstrogens, Conjugated26$13,206
FemringEstradiol Acetate13$9,860
YuvafemEstradiol39$8,239
ProgesteroneProgesterone, Micronized125$6,587
ValacyclovirValacyclovir Hcl26$1,655
Estradiol (Once Weekly)Estradiol11$1,458
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet16$1,456
DottiEstradiol13$1,200
Escitalopram Oxalate13$473
Clobetasol Propionate13$387
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$309
Fluconazole24$192
Acyclovir14$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$17,597$13,20626 claims
Millicent US IncFemring$197$9,86013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other gynecology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →